Free

On autism and Tylenol at Kenvue & JNJ’

The Tylenol causes autism thing seems to have taken on a life of its own the past few days, after President Trump repeatedly warned pregnant women on Tuesday, despite exceedingly thin scientific evidence, to “fight like hell not to take it.”

Yesterday, the White House even resurfaced a Tweet from over eight years ago that it said proved that Johnson & Johnson, the company that used to own Tylenol before spinning it off into a new company called Kenvue Inc. in May 2023, knew that the common over-the-counter drug was dangerous for pregnant women.

Needless to say, JNJ’s filings tell a different story. The only mention of Tylenol as it relates to autism was in its 2022 10-K that was filed in Feb. 2023. In that filing, the company disclosed for the first time that:

Claims for personal injury have been made against Johnson and Johnson Consumer Inc. (JJCI), arising out of the use of TYLENOL, an over-the-counter pain medication, alleging that prenatal exposure to acetaminophen is associated with the development of autism spectrum disorder and/or attention-deficit/hyperactivity disorder. In October 2022, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the Southern District of New York. In addition, lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with TYLENOL related product liability litigation.
JNJ mentioned it in two additional filings — the 10-Qs that it filed in April and July of 2023 at which point it became Kenvue’s problem. In the S-1 that Kenvue filed on Jan. 4, 2023, it disclosed the lawsuits. Its most recent update — in the 10-Q filed on Aug, 7 said that “all remaining cases then pending” had been dismissed in August 2024, but were now on appeal.  “In August 2024, all remaining cases then pending in the multi-district litigation were dismissed. As of December 2024, all cases were on appeal. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases.”
Already, at least one of the attorneys involved in the litigation have pointed to the Trump Administration’s warnings as a reason not to dismiss the cases via a letter sent to the Appeals Court. According to this Reuters story, attorney Ashley Keller “told the appeals court that a ruling upholding the lower court’s decision to dismiss the cases for lack of scientific evidence would pose grave separation of powers concerns”.
Kenvue hasn’t filed anything with the SEC since the Aug. 7 Q. It will be interesting to see if it winds up filing an 8-K in light of recent events or waits until its next 10-Q in November. And JNJ hasn’t mentioned it in their filings since July 2023, shortly after the spin-off.